Xeris Biopharma Holdings (XERS) Goodwill & Intangibles (2021 - 2026)

Xeris Biopharma Holdings (XERS) has 6 years of Goodwill & Intangibles data on file, last reported at $108.2 million in Q1 2026.

• Quarterly Goodwill & Intangibles fell 9.11% year-over-year to $108.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $108.2 million (down 9.11% YoY) and the FY2025 annual result came in at $110.9 million, down 8.9% from the prior year.
• Goodwill & Intangibles fell to $108.2 million in Q1 2026, from $110.9 million in the prior quarter.
• In the past five years, Goodwill & Intangibles ranged from a high of $151.6 million in Q1 2022 to a low of $108.2 million in Q1 2026.
• A 5-year average of $129.9 million and a median of $129.9 million in 2024 frame the typical range for Goodwill & Intangibles.
• Annual changes were most pronounced in 2022 — Goodwill & Intangibles dropped 7.03% — and 2026, when it slipped 9.11%.
• Tracing XERS's Goodwill & Intangibles over 5 years: stood at $143.5 million in 2022, then decreased by 7.56% to $132.6 million in 2023, then declined by 8.18% to $121.8 million in 2024, then dropped by 8.9% to $110.9 million in 2025, then fell by 2.44% to $108.2 million in 2026.
• The last three Goodwill & Intangibles figures came in at $108.2 million (Q1 2026), $110.9 million (Q4 2025), and $113.6 million (Q3 2025), per Business Quant data.